Scapa Group PLC Directorate Change (7188Q)
23 Giugno 2020 - 8:00AM
UK Regulatory
TIDMSCPA
RNS Number : 7188Q
Scapa Group PLC
23 June 2020
23 June 2020
LEI No. 213800QIPVTK5ES5UU36
Scapa Group plc
('Scapa' or 'the Company')
Directorate Change
Scapa Group plc (AIM: SCPA), a diversified Healthcare and
Industrial company focused on bringing best-in-class innovation,
design and manufacturing solutions to its customers, announces that
having served as Chairman of the Company for over three years,
Larry Pentz has decided not to offer himself for re-election at the
2020 Annual General Meeting (AGM). The Board has approved the
appointment of Chris Brinsmead CBE as Larry's successor. Chris's
appointment as Non-Executive Chairman will be effective from 7
August 2020 and he will offer himself for election at the AGM that
same day. It has been agreed that Chris will commence his induction
programme ahead of his appointment.
Chris has worked in the global healthcare sector for over forty
years and has held a number of senior executive leadership
positions. Chris is currently Chairman of Collagen Solutions plc
and Proveca Ltd. He was previously Chairman of Consort Medical plc
and the Senior Independent Director of UDG Healthcare plc. Chris
was also formerly Chairman of AstraZeneca Pharmaceuticals UK,
President of AstraZeneca UK and Ireland and President of the
Association of the British Pharmaceutical Industry (ABPI). He has
also held board positions at the Wesleyan Assurance Society, Domino
Printing Sciences plc, Cambian Group plc and Kinapse Ltd. Chris is
a Member of Council at Imperial College and was previously an
advisor and champion of Life Sciences to the UK Government. Chris
holds a BSc in Civil Engineering from Nottingham University and an
MSc in Business Science from Manchester Business School.
Commenting on the changes, Heejae Chae, Chief Executive Officer,
said:
"On behalf of the Board, I would like to express our thanks to
Larry for his service, leadership and guidance over the past three
years. Larry has chaired Scapa through a period of transition,
witnessing the growth of our healthcare business and departs with
our best wishes for the future.
"We are delighted to welcome Chris to Scapa. He is an
established senior board member with a wealth of healthcare
experience and significant international, operational and strategic
expertise."
Larry Pentz added:
"I have enjoyed being part of the transformative journey of
Scapa in which the Company has strengthened its market position,
expanded, enhanced and optimised its business offering and built a
strong platform for growth."
Commenting on his appointed, Chris Brinsmead, said:
"I look forward to joining the Board of Scapa and building on
the Company's strong market position as a trusted partner to
capitalise on the outlook and opportunities for the Healthcare and
Industrial business divisions."
The Company makes the following disclosures in relation to Chris
Brinsmead's appointment in accordance with paragraph (g) of
Schedule Two of the AIM Rules for Companies:
In addition to the appointment to the Board, Christopher David
Brinsmead, aged 61, holds or has held the following directorships
and partnerships in the past five years:
Current directorships/partnerships Previous directorships/partnerships
held in the last 5 years
CDB (Meadowside) Limited Kinapse Limited
====================================
P roveca Limited Bamburgh Capital Limited
----------------------------------- ------------------------------------
C ollagen S olutions PLC Cambian Group Limited
----------------------------------- ------------------------------------
Datapharm Communications Limited
----------------------------------- ------------------------------------
Consort Medical Plc
----------------------------------- ------------------------------------
UDG Healthcare Plc
----------------------------------- ------------------------------------
Wesleyan Assurance Society
====================================
Chris Brinsmead is currently interested in a total of 20,000
ordinary shares of 5p each in the Company.
For further information:
Scapa Group plc
Heejae Chae - Group Chief Executive
Oskar Zahn - Chief Finance Officer 0161 301 7430
Numis Securities Limited
(Nominated Adviser and Joint Broker)
Freddie Barnfield/Mark Lander 020 7260 1000
Berenberg
(Joint Broker)
Chris Bowman/Toby Flaux 020 3207 7800
FTI Consulting
(Media Relations)
Simon Conway/Victoria Foster Mitchell 020 3727 1000
About Scapa Group plc
Scapa Group plc is a diversified Healthcare and Industrial
company focused on bringing best-in-class innovation, design and
manufacturing solutions to its customers.
Healthcare
Scapa Healthcare is the trusted strategic partner of choice for
the world's leading companies in Advanced Wound Care, Consumer
Wellness and Medical Device Fixation. We partner with the top
global MedTech companies to develop and manufacture innovative skin
friendly medical device fixation and topical solutions, from
inception through to market delivery, from our state-of-the-art
facilities.
For further information, please visit
www.scapahealthcare.com
Industrial
Scapa Industrial is a global supplier of bonding solutions and
manufacturer of adhesive-based products which offer meaningful
value in industrial applications due to their lightweight,
easy-to-apply properties. We are recognised for our unparalleled
range of products, including adhesive tapes, films and foams, and
we can engineer custom designs for even the most unique
applications.
For further information, please visit
www.scapaindustrial.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOASEMESEESSELM
(END) Dow Jones Newswires
June 23, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Scapa (LSE:SCPA)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Scapa (LSE:SCPA)
Storico
Da Apr 2023 a Apr 2024